<div id="readability-page-1">Insmed Incorporated announced that a recent study focusing on brensocatib did not reach its primary or secondary efficacy goals. Consequently, the company has decided to halt the program for treating HS. Despite this setback, the safety profile of brensocatib remains in line with earlier studies, with no new safety concerns detected for either dosage used. The announcement was made on April 7, 2026, from the company's headquarters in Bridgewater, New Jersey.</div>

INSM

<p>Insmed Incorporated announced that a recent study focusing on brensocatib did not reach its primary or secondary efficacy goals. Consequently, the company has decided to halt the program for treating HS. Despite this setback, the safety profile of brensocatib remains in line with earlier studies, with no new safety concerns detected for either dosage used. The announcement was made on April 7, 2026, from the company's headquarters in Bridgewater, New Jersey.</p>

Unusual Whales

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Insmed

Direxion S&P Biotech Bull 3X

iShares US Pharma

Invesco Dorsey Wright Healthcare Momentum ETF

BNY Mellon Innovators ETF

iShares Biotechnology ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

Direxion S&P Biotech Bear 3X

Health Care Select Sector SPDR

VG Health

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Insmed Provides Clinical Update on Phase 2b CEDAR Study